Amedisys (NASDAQ:AMED) Sees Large Volume Increase – What’s Next?

Amedisys, Inc. (NASDAQ:AMED) shares saw unusually-high trading volume on Tuesday . Approximately 893,598 shares traded hands during mid-day trading, an increase of 167% from the previous session’s volume of 334,064 shares.The stock last traded at $96.94 and had previously closed at $94.22.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Wall Street Zen cut Amedisys from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 24th. Stephens reissued an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $100.75.

Amedisys Trading Up 2.9%

The company’s fifty day simple moving average is $93.66 and its two-hundred day simple moving average is $91.76. The company has a market capitalization of $3.18 billion, a price-to-earnings ratio of 38.44, a price-to-earnings-growth ratio of 1.78 and a beta of 0.94. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. During the same quarter last year, the business posted $1.03 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. Research analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amedisys

Institutional investors and hedge funds have recently modified their holdings of the business. Trexquant Investment LP raised its holdings in Amedisys by 1,317.8% during the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider’s stock worth $7,964,000 after buying an additional 81,532 shares during the period. ABC Arbitrage SA acquired a new stake in shares of Amedisys during the fourth quarter worth $2,522,000. Schonfeld Strategic Advisors LLC raised its holdings in shares of Amedisys by 17.5% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider’s stock worth $409,000 after acquiring an additional 671 shares during the period. Deutsche Bank AG lifted its position in Amedisys by 22.7% in the 4th quarter. Deutsche Bank AG now owns 2,524 shares of the health services provider’s stock valued at $229,000 after acquiring an additional 467 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in Amedisys in the 4th quarter worth $318,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.